[go: up one dir, main page]

WO2009133430A1 - Compositions topiques de rhéine ou de diacéréine - Google Patents

Compositions topiques de rhéine ou de diacéréine Download PDF

Info

Publication number
WO2009133430A1
WO2009133430A1 PCT/IB2008/053856 IB2008053856W WO2009133430A1 WO 2009133430 A1 WO2009133430 A1 WO 2009133430A1 IB 2008053856 W IB2008053856 W IB 2008053856W WO 2009133430 A1 WO2009133430 A1 WO 2009133430A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
polyethylene glycol
alcohol
bases
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/053856
Other languages
English (en)
Inventor
Roshanlal Sandal
Rahul Dabre
Girish Kumar Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Research Centre
Original Assignee
Wockhardt Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Centre filed Critical Wockhardt Research Centre
Publication of WO2009133430A1 publication Critical patent/WO2009133430A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the invention relates to topical pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions.
  • rhein is 9,10-diDhyDdro-4, 5-dihydroxy-9, lO-dioxo-2-anthracene carboxylic acid having a structure of Formula I and diacerein is 4,5-bis (acetyloxy) 9,10-dihydro-4, 5-dihydroxy-9, lO-dioxo-2-anthracenecarboxylic acid having a structure of Formula II.
  • Diacerein is widely used in the treatment of osteoarthritis and has a unique mode of action that differentiates it from non-steroidal anti-inflammatory drugs (NSAIDs) and other conventional forms of drug therapy.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Diacerein is practically insoluble in solvents such as water, alcohols, acetone, dichloromethane and chloroform, which are generally used in pharmaceutical preparations. Although diacerein can be administered by oral route but it cannot be completely absorbed by the digestive tract, and this incomplete absorption may result in undesirable side effects such as, soft stools .
  • EP 243,968 discloses a potassium salt of diacerein, which is water- soluble and can be used in the preparation of compositions for parenteral admin- istration .
  • European Patent No EP904060 discloses pharmaceutical compositions of rhein or diacerein, wherein rhein or diacerein is co-micronized with sodium lauryl sulfate.
  • U.S. Patent No. 5,952,383 and European Patent No. EP 862423B1 describe pharmaceutical compositions of diacerein, rhein and their salts along with liquid support systems like oils, suspending agents, homogenizing agents and other excipients .
  • Topical compositions are useful for obvious reasons. First, these do not impart any systemic side effects inside the body. Second, these are easy to apply and thus are more convenient for patients. A topical formulation can be applied to the place of treatment easily and painless even when applied by the patient. Topical formulations are also more preferred than oral ones for patients who suffer from dysphagia or are averse to the taste of the medicine. A specific advantage of topical formulations is that the patient can, either at first sight or by touching his skin, easily ascertain whether he has applied the medicine or not, thereby the risk of inadvertent overdosing or under dosing considerably decreases. Summary of the Invention [13] In one general aspect there is provided a topical pharmaceutical composition comprising rhein or diacerein, or salts or esters or prodrugs thereof.
  • a topical composition comprising rhein or diacerein, salts or esters or prodrug thereof, wherein the composition exhibits a dissolution profile such that more than 60% of diacerein is released within 4 hrs, wherein the release rate is measured in Franz diffusion cell at 50 rpm using 50 ml of pH 5.7 phosphate buffer at 37 0 C + 0.5 0 C.
  • a process for the preparation of a topical composition comprising rhein or diacerein, salts or esters or prodrugs thereof, the process comprising dissolving or suspending rhein or diacerein, or salts or esters or prodrugs thereof in one or more solvents or bases; and mixing with other pharmaceutically acceptable excipients.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the pharmaceutical composition may further include one or more pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients may include one or more of fillers, binders, lubricants, sweeteners, coloring and flavoring agents, glidants, disintegrants, and the like.
  • the topical compositions may be present in the form of a lotion, cream, ointment, paste, gel, spray, suspension, emulsion, foam, patch, powder or liniment.
  • a topical composition may be prepared by dissolving or suspending rhein or diacerein, or salts or esters or prodrug thereof in one or more solvents or bases; and mixing the product thus obtained with one or more pharmaceutically acceptable excipients.
  • the one or more pharmaceutically acceptable excipients may be selected from the group of emulsifiers, wetting agents or surfactants, chelating agents, solvents, antioxidants, gelling agents, thickening agent or viscosity-enhancing agents, waxes, penetration enhancers, solubilizing agents, buffering agents, emollients, bases, coloring agents, flavoring agents, preservatives, and the like.
  • Suitable wetting agents or surfactants include one or more of docusate sodium, PEG derivatives, quaternary ammonium compounds, such as benzalkonium chloride, ben- zethonium chloride and cetylpyridinium chloride; TPGS (d- alpha tocopheryl polyethylene glycol succinate), dioctyl sodium sulfosuccinate; poly oxy ethylene alkylphenyl ethers, such as nonoxynol 9, nonoxynol 10, and octoxynol 9; poloxamers (poly oxy ethylene and polyoxypropylene block copolymers); poly oxy ethylene fatty acid glycerides and oils, such as poly oxye thy lene (8) caprylic/capric mono- and diglycerides (e.g., Labrasol.TM., Gattefosse), polyoxyethylene (35) castor oil and poly oxy ethylene (40) hydrogenated castor oil; polyoxyethylene alkyl
  • propylene glycol fatty acid esters such as propylene glycol laureate (e.g., Lauroglycol.TM., Gattefosse); sodium lauryl sulfate; fatty acids and salts thereof, such as oleic acid, sodium oleate and triethanolamine oleate; glyceryl fatty acid esters, for example glyceryl monostearate; sorbitan esters, such as sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate; tyloxapol; lecithin; stearyl triethanolamine; laurylamino- propionic acid; and mixtures thereof.
  • propylene glycol fatty acid esters such as propylene glycol laureate (e.g., Lauroglycol.TM., Gattefosse); sodium lauryl sulfate; fatty acids and salts thereof, such as oleic acid, sodium o
  • Chelating agents may be added to trap metals that find their way into the compositions during processing.
  • Suitable chelating agents may include, but are not limited to, one or more of ethylenediaminetetraacetic acid (EDTA), ethylenediamine (EDA), diethylenetriamine (DETA), aminoethylethanolamine (AEEA).
  • EDTA ethylenediaminetetraacetic acid
  • EDA ethylenediamine
  • DETA diethylenetriamine
  • AEEA aminoethylethanolamine
  • Thickening agents or viscosity-enhancing agents may be included to generally improve the mouth-feel of the composition and/or to help coat the lining of the gastrointestinal tract.
  • thickening agents include acacia, alginic acid bentonite, polyvinyl pyrrolidone, magnesium aluminium silicate, carbomer, microcrystalline cellulose, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, glycerin, gelatin guar gum, hydroxyethyl cellulose, hy- droxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum.
  • suitable solvents include, but not limited to, one or more of alcohol, castor oil, diisopropyl adipate, ethoxylated alcohol, ethyl alcohol, fatty alcohol citrate, glycerin, 1,2,6-hexanetriol, hexylene glycol, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, mineral oil, phosphoric acid, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 1450, polyethylene glycol 8000, polyethylene glycol 1000 monocetyl ether, polyethylene glycol monostearate, polyethylene glycol 400 monostearate, polyethylene glycols, polyoxyl 20 cetostearyl ether, polyoxypropylene 15-stearyl ether, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbates, propylene carbonate, propylene glycol, purified water, SD alcohol 40, triglycerides of saturated fatty acids
  • Suitable antioxidants may include, but not limited to, one or more of Vitamin C, vitamin A and alpha-lipoic acid, ascorbyl palmitate, sodium pyrosulfite, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT), and the like.
  • Suitable gelling agents may include, but not limited to, one or more of guar, xanthan, and carregeenan gums, anionic, nonionic, cationic and lipophilically modified guar gums, polyacrylic acids, polymethacrylic acids, cellulose resins, polyethylene glycols, hydroxy alkyl celluloses, carboxy alkyl celluloses, polyalkylene amines, and the like.
  • waxes examples include beeswax, Montan wax, Carnauba wax, Candelilla wax,
  • Suitable penetration enhancers may include one or more of diethylene glycol monoethyl ether, dimethyl sulfoxide, propylene glycol, isopropyl myristate (IPM), cal- cipotriene, detergents, emollients, Ethoxy diglycol, Triacetin, Propylene Glycol, Benzyl Alcohol, Sodium Laureth Sulfate, Dimethyl Isosorbide, Isopropyl Myristate, Medium Chain Triglyceride Oil (MCT Oil), Menthol, Isopropyl Palmitate, Isopropyl Isostearate, Propylene Glycol Monostearate, Lecithin, Diisopropyl Adipate, Diethyl Sebacate, Oleic Acid, Ethyl Oleate, Urea, Glyceryl Oleate, Caprylic/Capric Triglyceride, Propylene Glycol Dicaprylate/Dicaprate, Laureth
  • Solubilizing agents may be used to facilitate more uniform dispersion of an active ingredient or other excipient that is not generally soluble in the liquid carrier.
  • suitable solubilizing agents include gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methylcellulose, carbomer, cetostearyl alcohol, cetyl alcohol, glycol, glycerin, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, and mixtures thereof.
  • Suitable buffering agents may include, but are not limited to, one or more of sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, aluminum hydroxide, aluminum hydroxide/sodium bicarbonate co precipitate, amino acids, aluminum glycinate, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, sodium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and the like.
  • Suitable humectants may include, but not limited to, one or more of, glycerol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, pantothenol, gluconic acid salts, and the like.
  • Suitable emollients may include, but not limited to, one or more of glycerol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, pantothenol and gluconic acid salts, and the like.
  • Suitable bases may be in the form of oleaginous bases, absorption bases, water in oil emulsion bases, oil in water emulsion bases, water soluble or water miscible bases.
  • Suitable bases may be in the form of oil or fat bases.
  • Suitable bases may include but not limited to one or more of, natural wax e.g. white and yellow bees wax, carnauba wax, wool wax (wool fat), purified lanolin, anhydrous lanolin, petroleum wax e.g. hard paraffin, microcrystalline wax, hydrocarbons e.g. liquid paraffin, white and yellow soft paraffin, white petrolatum, yellow petrolatum, and the like.
  • Colorant agents suitable for inclusion in the present invention may include, but not limited to, one or more water-soluble synthetic organic food additives (e.g., food dyes such as food red dye Nos. 2 and 3, food yellow dye Nos. 4 and 5 and food blue dye Nos. 1 and 2), water-insoluble lake dyes (e.g., aluminum salts of the above water-soluble synthetic organic food additives, etc.), and natural pigments (e.g., beta-carotene, chlorophyll, iron oxide red, etc.).
  • Suitable colorants include D&C Red No. 33, FD&C Red No. 3, FD&C Red No. 40, D&C Yellow No. 10, and C Yellow No. 6.
  • Suitable flavoring agents may include those known to a skilled artisan, such as natural, 'natural-like' and artificial flavors. These flavors may be selected from synthetic flavor oils, flavoring aromatics, oleo-resins and extracts derived from plants, leaves, flowers or fruits.
  • Representative flavors may include, but not limited to, one or more of spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, vanilla, chocolate, coffee, cocoa and citrus oil, lemon, orange, cherry, grape, lime or grapefruit, and fruit essences, e.g. apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple or apricot; mints such as peppermint (including menthol, especially levomenthol), aldehydes and esters, e.g.
  • the preservative may be added to the compositions at levels safe for ingestion to improve storage stability.
  • Suitable preservative may include, but not limited to, one or more of sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole, ethylenediamine tetraacetic acid, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid, sorbic acid, benzalkonium chloride, benzethonium chloride, phenol, phenylmercuric nitrate, Thimerosal.
  • Diacerein was mixed with propylene glycol to form a wet diacerein.
  • Petrolatum, mineral oil, cetostearyl alcohol were added to hot water to form a clear liquid.
  • the clear liquid was cooled to form a cream base.
  • the wet diacerein was added to the above cream base with trituration to form cream.
  • Table 2 provides the dissolution data for diacerein cream prepared as per the formula given in Table 1.
  • 50 ml volume of 5.7 Tampon phosphate buffer at a speed of 50 rpm in Franz diffusion cell was used as a medium.
  • Table 4 provides the dissolution data for diacerein gel prepared as per the formula given in Table 11.
  • 50 ml volume of 5.7 Tampon phosphate buffer at a speed of 50 rpm in Franz diffusion cell was used as a medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des compositions pharmaceutiques topiques comprenant de la rhéine ou de la diacéréine, ou des sels ou esters ou promédicaments de celles-ci. L'invention porte également sur des procédés pour préparer de telles compositions.
PCT/IB2008/053856 2008-04-30 2008-09-23 Compositions topiques de rhéine ou de diacéréine Ceased WO2009133430A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN953/MUM/2008 2008-04-30
IN953MU2008 2008-04-30

Publications (1)

Publication Number Publication Date
WO2009133430A1 true WO2009133430A1 (fr) 2009-11-05

Family

ID=40293615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/053856 Ceased WO2009133430A1 (fr) 2008-04-30 2008-09-23 Compositions topiques de rhéine ou de diacéréine

Country Status (1)

Country Link
WO (1) WO2009133430A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004319A1 (fr) 2015-07-01 2017-01-05 Twi Biotechnology, Inc. Formulations topiques de rhéine ou de diacéréine, et utilisations de celles-ci
WO2017172603A1 (fr) * 2016-03-28 2017-10-05 Tioga Research, Inc. Formulation topique
CN107823126A (zh) * 2017-12-04 2018-03-23 广东药科大学 双醋瑞因注射型温敏凝胶及其制备方法
US10154984B2 (en) * 2015-07-01 2018-12-18 Twi Biotechnology, Inc. Diacerein or Rhein topical formulations and uses thereof
US10512625B2 (en) * 2015-07-01 2019-12-24 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
WO2021024150A1 (fr) * 2019-08-03 2021-02-11 Neuheit Pharma Technologies Pvt. Ltd Procédé pour la préparation de formulation topique d'anthraquinone

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215208A (en) * 1988-02-01 1989-09-20 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing a plant extract
WO2001064229A1 (fr) * 2000-02-29 2001-09-07 Jun Ho Co., Ltd. Medicament de traitement de l'obesite, sa preparation et son utilisation
CA2204210C (fr) * 1997-05-01 2003-02-18 Teh Shan Chang Preparation d'herboristerie et cataplasme fait a partir de celle-ci
JP2003095860A (ja) * 2001-09-20 2003-04-03 Koei Kogyo Kk 抗老化化粧料
EP1419781A1 (fr) * 2002-11-14 2004-05-19 ABOCA S.p.A. Usage odontostomatologique des composés d'origine vegetale à base de racines de rhubarbe (genre rheum) et feuilles d'épinard (spinacia oleracea l.)
US20050004045A1 (en) * 2000-01-12 2005-01-06 Guido Di Napoli Substances for use in treating psoriasis
WO2005049025A1 (fr) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Procede et composition de traitement de lesions cutanees
WO2005085293A1 (fr) * 2004-02-26 2005-09-15 Laboratoire Medidom Sa Esters d'acide hyaluronique comprenant de la rheine, procede de preparation associe et compositions comprenant lesdits esters
JP2005298505A (ja) * 2004-04-09 2005-10-27 Amorepacific Corp 高圧乳化技術を用いたダイオウ抽出物の経皮吸収促進方法及びこれを応用した美白用皮膚外用剤組成物
CN1883572A (zh) * 2006-05-31 2006-12-27 冯喜平 一种治疗静脉炎的软膏及其制备方法
DE202007015417U1 (de) * 2007-11-07 2008-02-21 Alexa, Mihai, Dipl.-Chem. Dr. Präparat zur Bekämpfung von Herpes labialis, Herpes vaginalis, Psoriasis, Schmerzen von Verbrennungen 1.ten und 2.ten Grades, infizierten Hautpartien und Neurodermitis
WO2008078166A2 (fr) * 2006-12-22 2008-07-03 Laboratoire Medidom S.A. Système in situ pour une réparation du tissu chondral et osseux intra-articulaire

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215208A (en) * 1988-02-01 1989-09-20 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing a plant extract
CA2204210C (fr) * 1997-05-01 2003-02-18 Teh Shan Chang Preparation d'herboristerie et cataplasme fait a partir de celle-ci
US20050004045A1 (en) * 2000-01-12 2005-01-06 Guido Di Napoli Substances for use in treating psoriasis
WO2001064229A1 (fr) * 2000-02-29 2001-09-07 Jun Ho Co., Ltd. Medicament de traitement de l'obesite, sa preparation et son utilisation
JP2003095860A (ja) * 2001-09-20 2003-04-03 Koei Kogyo Kk 抗老化化粧料
EP1419781A1 (fr) * 2002-11-14 2004-05-19 ABOCA S.p.A. Usage odontostomatologique des composés d'origine vegetale à base de racines de rhubarbe (genre rheum) et feuilles d'épinard (spinacia oleracea l.)
WO2005049025A1 (fr) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Procede et composition de traitement de lesions cutanees
WO2005085293A1 (fr) * 2004-02-26 2005-09-15 Laboratoire Medidom Sa Esters d'acide hyaluronique comprenant de la rheine, procede de preparation associe et compositions comprenant lesdits esters
JP2005298505A (ja) * 2004-04-09 2005-10-27 Amorepacific Corp 高圧乳化技術を用いたダイオウ抽出物の経皮吸収促進方法及びこれを応用した美白用皮膚外用剤組成物
CN1883572A (zh) * 2006-05-31 2006-12-27 冯喜平 一种治疗静脉炎的软膏及其制备方法
WO2008078166A2 (fr) * 2006-12-22 2008-07-03 Laboratoire Medidom S.A. Système in situ pour une réparation du tissu chondral et osseux intra-articulaire
DE202007015417U1 (de) * 2007-11-07 2008-02-21 Alexa, Mihai, Dipl.-Chem. Dr. Präparat zur Bekämpfung von Herpes labialis, Herpes vaginalis, Psoriasis, Schmerzen von Verbrennungen 1.ten und 2.ten Grades, infizierten Hautpartien und Neurodermitis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200167, Derwent World Patents Index; Class A96, AN 2001-596753, XP002513744, FUJIMOTO M: "Drug for treating obesity containing Chinese herbs, especially suitable for external application as medicated plaster to navel or Qi point, made by specific extraction of various ingredients and combining the extracts for formulation" *
DATABASE WPI Section Ch Week 200365, Derwent World Patents Index; Class B04, AN 2003-683063, XP002513745, HONDA H ET AL: "Cosmetics for preventing aging of skin, comprise solvent extract of Eythroxylum catuaba, Erthroxylum macrophyllum or Erythroxylum vaccinifolium, belonging to the Erythroxylaceae, as active ingredients" *
DATABASE WPI Section Ch Week 200577, Derwent World Patents Index; Class B04, AN 2005-753488, XP002441896, KAN B Y ET AL: "External preparation e.g. skin lotion, cream, pack, body cream, makeup base or foundation, for providing fairness to skin, contains fine emulsified particle or fine liposome containing rhubarb extract as active ingredient" *
DATABASE WPI Section Ch Week 200748, Derwent World Patents Index; Class A96, AN 2007-482820, XP002513743, CHEN J; FENG X: "Ointment for treating phlebitis and method for preparing same" *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021229177B2 (en) * 2015-07-01 2023-11-23 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
KR102702557B1 (ko) 2015-07-01 2024-09-03 티더블유아이 바이오테크놀로지 인코포레이티드 디아세레인 또는 레인 국소 제형 및 이의 용도
KR20180023965A (ko) * 2015-07-01 2018-03-07 티더블유아이 바이오테크놀로지 인코포레이티드 디아세레인 또는 레인 국소 제형 및 이의 용도
JP2024164022A (ja) * 2015-07-01 2024-11-26 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド ジアセレインまたはレインの局所製剤およびその使用
CN107921013A (zh) * 2015-07-01 2018-04-17 安成生物科技股份有限公司 双醋瑞因或大黄酸局部用制剂及其用途
JP2018522875A (ja) * 2015-07-01 2018-08-16 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． ジアセレインまたはレインの局所製剤およびその使用
US10154984B2 (en) * 2015-07-01 2018-12-18 Twi Biotechnology, Inc. Diacerein or Rhein topical formulations and uses thereof
US10512625B2 (en) * 2015-07-01 2019-12-24 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
JP7578651B2 (ja) 2015-07-01 2024-11-06 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド ジアセレインまたはレインの局所製剤およびその使用
JP7577428B2 (ja) 2015-07-01 2024-11-05 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド ジアセレインまたはレインの局所製剤およびその使用
AU2016287636B2 (en) * 2015-07-01 2021-09-16 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
JP2022169600A (ja) * 2015-07-01 2022-11-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド ジアセレインまたはレインの局所製剤およびその使用
WO2017004319A1 (fr) 2015-07-01 2017-01-05 Twi Biotechnology, Inc. Formulations topiques de rhéine ou de diacéréine, et utilisations de celles-ci
US10716754B2 (en) 2016-03-28 2020-07-21 Tioga Research, Inc. Topical formulation
WO2017172603A1 (fr) * 2016-03-28 2017-10-05 Tioga Research, Inc. Formulation topique
CN107823126A (zh) * 2017-12-04 2018-03-23 广东药科大学 双醋瑞因注射型温敏凝胶及其制备方法
WO2021024150A1 (fr) * 2019-08-03 2021-02-11 Neuheit Pharma Technologies Pvt. Ltd Procédé pour la préparation de formulation topique d'anthraquinone

Similar Documents

Publication Publication Date Title
EP0672422B1 (fr) Gel transdermique antiinflammatoire et analgésique contenant du Ketoprofène
ES2435816T3 (es) Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
ES2330188T3 (es) Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
JP2008517935A (ja) ジクロフェナクを含む医薬組成物
CN104168895A (zh) 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
WO2009133430A1 (fr) Compositions topiques de rhéine ou de diacéréine
US20110086070A1 (en) Orally disintegrating compositions of rhein or diacerein
US9119819B2 (en) Oral liquid compositions of rhein or diacerein
CN102014904A (zh) 具有适口味道的去铁酮液体配制品
JP2013515782A (ja) オンダンセトロンを含む経口投与可能なフィルム製剤
CN100518726C (zh) 莫达非尼化合物的药用溶液
US6551615B1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2002356421A1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
CN111825548B (zh) 一种含有芳基丙酸类化合物的药物组合物
CN100584322C (zh) 包含莫达非尼化合物的组合物
Rajab et al. Preparation and characterization of lacidipine as an oral fast dissolving film
CN114452255A (zh) 一种阿戈美拉汀微乳、微乳凝胶及其制备方法
WO2003101378A2 (fr) Formulation pharmaceutique dans un systeme d'administration de medicaments et son procede de preparation
JP2015507006A (ja) ユリノキの樹皮のエキスを有効成分として含有する改善された医薬製剤
WO2021061913A1 (fr) Solution topique de diclofénac sodique
JP2016540748A (ja) オンダンセトロン舌下スプレー製剤
CN118615260A (zh) 一种吡仑帕奈口溶膜的药物组合物及其制备方法
EP1242062B1 (fr) Compositions pharmaceutiques pour l'administration topique dans la cavite buccale de produits anti-inflammatoires non steroides
JPS62223119A (ja) 外用クリ−ム製剤
CN114306234A (zh) 一种含有加巴喷丁复合物的tpgs胶束口服液及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807764

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807764

Country of ref document: EP

Kind code of ref document: A1